PETCT and lung cancer: Selecting those likely to benefit and sparing those with little to gain

Author(s): Dr Peter J G Garmany

Hospital: Queen Elizabeth University Hospital and West of Scotland Cancer Centre

Reference: RAD Magazine, 44, 523, 25-26


Lung cancer is the third commonest cancer in the UK and 75% of patients present with advanced disease (stage III or IV); 10-year survival is only 5%.

PETCT is best considered as a tool that aids the selection of those most likely to benefit from potentially curative treatment, either surgical resection or radical radiotherapy, while sparing those whose disease is so advanced that this approach would be futile.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read more